Our gene quantitation analysis of CD133 in cell lines from metastatic melanoma patients with poor clinical outcomes and short overall survival strongly supports our hypothesis that CD133 is a reliable marker of disease recurrence and an abundance of CD133 transcripts may play a pivotal role in progression of human cutaneous melanoma. This evidence concerns the gene PROM1 and cutaneous melanoma.